Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | EP102 |
| Synonyms | |
| Therapy Description |
EP102 inhibits METTL3, potentially resulting in decreased tumor cell proliferation and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 6282, Cancer Res (2025) 85 (8_Supplement_1): 5714). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| EP102 | EP-102|EP 102 | EP102 inhibits METTL3, potentially resulting in decreased tumor cell proliferation and inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 6282, Cancer Res (2025) 85 (8_Supplement_1): 5714). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07163325 | Phase I | EP102 | EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors | Recruiting | NLD | ESP | CZE | BEL | 0 |